Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > We will never know

<< Previous

Bullboard Posts

Next >>

Comment by AntibeTribeon Jan 27, 2021 7:35pm

135 Views

Post# 32404502

RE:We will never know

Layth1990 wrote:
We might wake up tomorrow with partnership news, or listing. No one really knows what will happen tomorrow since those kind of news/information are kept confidential until the release.

The real question is with who???Personally, I think big pharma (PFE, LLY or most likely given Haut, BY) partnership is the most likely scenario here. With that said, the amount of time between now and the end of q2 is looking oddly similar to the time frame of Hauts last deal.. I won't be surprised to open an email sometime this summer that says we've been acquired either!

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market